Xlife Sciences AG (SWX:XLS)
Switzerland flag Switzerland · Delayed Price · Currency is CHF
20.40
+0.55 (2.77%)
Last updated: Jun 2, 2025

Xlife Sciences AG Company Description

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector.

The company’s project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data.

It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services.

In addition, the company builds a bridge between research/ development and healthcare markets, as well as support researchers and entrepreneurs in the positioning, structuring, development, and implementation of their ideas; and operates as an active ingredient manufacturer.

Further, it focuses on identifying innovative biomarkers in the field of kidney diseases; the development of antibody-drug conjugates through a click chemistry approach and microfluidic screening of functional antibodies; and provides Neuromex, a screening instrument for the early-stage detection of neurological diseases.

Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.

Xlife Sciences AG
Country Switzerland
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Oliver Baumann

Contact Details

Address:
Talacker 35
Zurich, 8001
Switzerland
Phone 41 44 385 84 60
Website xlifesciences.ch

Stock Details

Ticker Symbol XLS
Exchange SIX Swiss Exchange
Fiscal Year January - December
Reporting Currency CHF
ISIN Number CH0461929603
SIC Code 8731

Key Executives

Name Position
Oliver R. Baumann Chief Executive Officer and Executive Director
Carl von Halem Chief Financial Officer
Beat Klaui Head of Accounting and Taxation
Dr. Alexander Zink Head of Technology and Innovation
Dr. Frank Ploger Chief Scientific Officer
Dr. Dennis Fink Senior Communications and Investor Relations Manager
Christian Faber Head of Legal and Compliance